BFM
BBIO icon

Boothbay Fund Management’s BridgeBio Pharma BBIO Stock Holding History

Boothbay Fund Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30,000
Closed -$516K – 1733
2023
Q2 		$516K Buy
+30,000
New +$451K 0.01% 1084
2022
Q1 		– Sell
-210,800
Closed -$3.52M – 2271
2021
Q4 		$3.52M Buy
+210,800
New +$8.92M 0.08% 295

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's BBIO Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 46,981 shares worth $3.49M. The stake represents 0.05% of the portfolio and ranks #419 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in BBIO as recently as Q3 2025.

Boothbay Fund Management first reported a position in BBIO in Q4 2021 and has held it in 12 quarters since. The position peaked at $4.21M in Q4 2023. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Boothbay Fund Management held 46,981 shares of BridgeBio Pharma worth $3.49M as of Q1 2026.
  • BridgeBio Pharma was a new Boothbay Fund Management position in Q1 2026.
  • BridgeBio Pharma made up 0.05% of Boothbay Fund Management's portfolio in Q1 2026, its #419 holding.
  • Boothbay Fund Management first reported a position in BridgeBio Pharma in Q4 2021 and has held it in 12 quarters since.
  • Boothbay Fund Management's BridgeBio Pharma position peaked at $4.21M in Q4 2023.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.